Table 1. Effect of anabolic treatments on vertebral and nonvertebral fracture risk in postmenopausal women with osteoporosis.

Drug	Trial	Comparator	Duration (months)	Vertebral fracture RRR	Non-vertebral fracture RRR
Teriparatide	FPT16	Placebo	21	65%	53%
	VERO20	Risedronate	24	56%	34%
	ACTIVE36	Placebo	18	80%	28%b
Abaloparatide	ACTIVE36	Placebo	18	86%	43%
Romosozumab	FRAME41	Placebo	12	73%	25%
	ARCH44a	Alendronic acid	24	37% (12 months) 48% (24 months)	26% (12 months) 19% (24 months)

^aRomosozumab for 12 months followed by alendronic acid for 12 months vs. alendronic acid for 24 months. ^bNon-significant (relative risk 0.72 [95% confidence interval 0.42–1.22], P = 0.22). RRR = relative risk reduction